Solution: To develop and set up production of a COVID-19 serology test, that can give greater detail into the prevalence of the disease in a population by identifying individuals who have developed antibodies to the virus. In contrast to RT-PCR tests that indicate the presence of viral material during infection, the serology tests can indicate if a person was infected and subsequently recovered by looking at their immune response. The team has already developed an original testing system called NAISSA, that has the capacity to conduct 30 different tests for SARS-CoV-2 at the same time, with 60-90 minutes per one testing session. Unlike the rapid serology tests that detect only the presence of antibodies, this test detects their level as well. The NAISSA testing system uses a desktop testing device that can be placed in any laboratory or hospital room and does not require highly trained personnel, so the medical staff can be quickly and easily trained to use it.